Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. Januar 2026 04:00 ET | Quelle: Hummingbird Bioscience

Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

Hummingbird Bioscience today announced that the first patient has been dosed in a Phase I clinical trial of HMBD-501.
05. Januar 2026 16:05 ET | Quelle: Revolution Medicines, Inc.

Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
05. Januar 2026 05:00 ET | Quelle: ProPhase Labs, Inc.

ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value

UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) today provided an update to shareholders regarding recent trading activity, its capital structure, and the...
05. Januar 2026 01:16 ET | Quelle: Burning Rock Biotech Limited

Burning Rock Announces Founder’s Purchase of Its ADSs

Burning Rock Announces Founder’s Purchase of Its ADSs
29. Dezember 2025 06:00 ET | Quelle: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

STAFFORD, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
22. Dezember 2025 23:04 ET | Quelle: Burning Rock Biotech Limited

Burning Rock Announces Results of 2025 Annual General Meeting

Burning Rock Announces Results of 2025 Annual General Meeting
22. Dezember 2025 07:00 ET | Quelle: Propanc Biopharma, Inc.

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Our findings demonstrate that PRP exerts multifaceted effects specifically over the cancer associated fibroblasts (CAFs) population and tumor cells.
20. Dezember 2025 11:46 ET | Quelle: Crosetto Foundation for the Reduction of Cancer Deaths

The 3D-Flow Architecture Breakthrough: A Universal, Scalable Digital Processor for Real-Time Pattern Recognition in High-Rate Data Streams — A Platform to Save Millions of Lives and Billions of Euros

From Physics to Healing: The same tech used to find particles can find cancer early. Why is this life-saving leap being suppressed?
19. Dezember 2025 07:00 ET | Quelle: Psyence Biomedical Ltd.

Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
18. Dezember 2025 08:00 ET | Quelle: Revolution Medicines, Inc.

Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...

Nächste Seite